Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy.
Bailén R, Alenda R, Herruzo-Delgado B, Acosta-Fleitas C, Vallés A, Esquirol A, Fonseca M, Solán L, Sánchez-Vadillo I, Bautista G, Bento L, López-Godino O, Pérez-Martínez A, Torrent A, Zanabili J, Calbacho M, Moreno MÁ, Pascual-Cascón MJ, Guerra-Domínguez L, Chinea A, García-Cadenas I, López-Corral L, Boix-Giner F, López Lorenzo JL, Humala K, Duarte R, Sampol A, Heras I, Vicario JL, Balas A, Oarbeascoa G, Fernández-Caldas P, Anguita J, Kwon M. Bailén R, et al. Among authors: heras i. Front Immunol. 2023 May 26;14:1165759. doi: 10.3389/fimmu.2023.1165759. eCollection 2023. Front Immunol. 2023. PMID: 37304258 Free PMC article.
Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
Ferrá C, Sanz J, de la Cámara R, Sanz G, Bermúdez A, Valcárcel D, Rovira M, Serrano D, Caballero D, Espigado I, Morgades M, Heras I, Solano C, Duarte R, Barrenetxea C, García-Noblejas A, Díez-Martin JL, Iriondo A, Carreras E, Sierra J, Sanz MA, Ribera JM; GETH (Grupo Español de Trasplante Hematopoyético) and PETHEMA (Programa Español de Tratamiento en Hematología), Spanish Society of Hematology. Ferrá C, et al. Among authors: heras i. Biol Blood Marrow Transplant. 2010 Jul;16(7):957-66. doi: 10.1016/j.bbmt.2010.02.003. Epub 2010 Feb 7. Biol Blood Marrow Transplant. 2010. PMID: 20144909 Free article.
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA. Caballero-Velázquez T, et al. Among authors: heras i. Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. Epub 2013 Jun 15. Br J Haematol. 2013. PMID: 23772672 Free article. Clinical Trial.
Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients.
Ferrà C, Sanz J, Díaz-Pérez MA, Morgades M, Gayoso J, Cabrera JR, Villaescusa T, Sampol MA, Fernández-Avilés F, Solano C, Ortín M, Duarte R, Cuesta M, Heras I, de la Serna J, Moraleda JM, Barrenetxea C, González-Vicent M, Sanz G, Ribera JM; Grupo Español de Trasplante Hematopoyético (Geth) Spanish Society of Hematology. Ferrà C, et al. Among authors: heras i. Leuk Lymphoma. 2015 Mar;56(3):656-62. doi: 10.3109/10428194.2014.930849. Epub 2014 Aug 4. Leuk Lymphoma. 2015. PMID: 24913510
The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J; Cooperative AML group CETLAM. Díaz-Beyá M, et al. Among authors: heras i. Oncotarget. 2015 Oct 13;6(31):31613-27. doi: 10.18632/oncotarget.5148. Oncotarget. 2015. PMID: 26436590 Free PMC article.
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M, Martin A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D. Cabrero M, et al. Among authors: heras i. Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. Epub 2016 Oct 19. Biol Blood Marrow Transplant. 2017. PMID: 27771496 Free article. Clinical Trial.
Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
Gayoso J, Balsalobre P, Kwon M, Herrera P, Bermúdez A, Sampol A, Jiménez S, López-Corral L, Serrano D, Piñana JL, Pascual MJ, Heras I, Bento L, Varela R, Humala K, Zabalza A, Laiglesia A, Bastos-Oreiro M, Pérez-Corral A, Martínez-Laperche C, Buño I, Díez-Martín JL; GETH (Grupo Español de Trasplante Hematopoyético), Spain. Gayoso J, et al. Among authors: heras i. Eur J Haematol. 2018 Sep;101(3):332-339. doi: 10.1111/ejh.13103. Epub 2018 Aug 3. Eur J Haematol. 2018. PMID: 29846964
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).
García-Cadenas I, Yáñez L, Jarque I, Martino R, Pérez-Simón JA, Valcárcel D, Sanz J, Bermúdez A, Muñoz C, Calderón-Cabrera C, García E, Alonso L, Suárez-Lledó M, González Vicent M, Heras I, Viguria MC, Batlle M, Vázquez L, López J, Solano C; Spanish group of blood and marrow transplantation (GETH). García-Cadenas I, et al. Among authors: heras i. Eur J Haematol. 2019 Jun;102(6):465-471. doi: 10.1111/ejh.13226. Epub 2019 Apr 10. Eur J Haematol. 2019. PMID: 30828868
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA. López-Corral L, et al. Among authors: heras i. Biol Blood Marrow Transplant. 2019 Sep;25(9):1703-1712. doi: 10.1016/j.bbmt.2019.04.026. Epub 2019 May 3. Biol Blood Marrow Transplant. 2019. PMID: 31054983 Free article. Clinical Trial.
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. Bastidas A, et al. JAMA. 2019 Jul 9;322(2):123-133. doi: 10.1001/jama.2019.9053. JAMA. 2019. PMID: 31287523 Free PMC article. Clinical Trial.
85 results